文献速递前列腺癌

双相雄激素治疗转移性去势抵抗性前列腺癌的多队列II期试验

A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
PubMed 文献 · Eur Urol · 2020-07-02

RESTORE研究是一项多队列开放标签II期试验,纳入29例阿比特龙后和30例恩扎卢胺后的无症状mCRPC患者,接受双相雄激素治疗(BAT),进展后重新挑战既往AR靶向治疗。BAT的PSA50应答率在两组间无显著差异,但恩扎卢胺后患者对AR靶向治疗再挑战的PSA50应答率更高,且PFS2更长;AR-V7阳性患者结局更差。

要点

  • BAT在mCRPC中有临床活性,但PSA50应答率在恩扎卢胺后与阿比特龙后队列无显著差异。
  • 恩扎卢胺后患者对AR靶向治疗再挑战的PSA50应答率和PFS2均优于阿比特龙后患者。
  • AR-V7阳性患者PFS2更短,BAT后AR靶向治疗再挑战未改善其结局。

核心结论

  • BAT在mCRPC患者中显示临床活性,可能对恩扎卢胺的再增敏效果优于阿比特龙。

研究设计与样本

  • RESTORE为多队列II期研究,纳入阿比特龙后29例和恩扎卢胺后30例无症状mCRPC患者,给予睾酮环戊丙酸酯400 mg肌注每28天并持续LHRH激动剂/拮抗剂治疗。

主要发现

  • BAT的PSA50应答率:恩扎卢胺后30% vs 阿比特龙后17%,p=0.4。
  • AR靶向治疗再挑战的PSA50应答率:恩扎卢胺后68% vs 阿比特龙后16%,p=0.001。
  • 再挑战后中位PFS2:恩扎卢胺后12.8个月 vs 阿比特龙后8.1个月,p=0.04。
  • 循环肿瘤细胞可检测AR-V7患者的中位PFS2为10.3 vs 7.1个月,p=0.005。

临床怎么用

  • BAT可作为mCRPC患者的一种治疗选择,尤其对恩扎卢胺后患者可能更好地恢复对AR靶向治疗的敏感性。
  • 对于AR-V7阳性患者,BAT后AR靶向治疗再挑战可能不改善结局,需谨慎选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cyclic high-dose testosterone injections, also known as bipolar androgen therapy (BAT), is a novel treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). BAT has shown clinical activity in prior studies enrolling men with mCRPC and may potentially restore sensitivity to prior androgen receptor (AR)-targeted agents. OBJECTIVE: To evaluate the clinical activity of BAT in patients progressing on AR-targeted therapy as well as responses to abiraterone or enzalutamide upon rechallenge after BAT. DESIGN, SETTING, AND PARTICIPANTS: RESTORE is a multicohort phase II study enrolling asymptomatic mCRPC patients after abiraterone or enzalutamide at Johns Hopkins Hospital (NCT02090114). Participants (29 after abiraterone and 30 after enzalutamide) received 400 mg testosterone cypionate intramuscularly every 28 days, with ongoing luteinizing hormone-releasing hormone agonist/antagonist treatment (ie, BAT). Following progression on BAT, patients were rechallenged with their most recent AR-targeted therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Coprimary endpoints were >50% decline in PSA from baseline (PSA50) responses to BAT and following AR-targeted therapy rechallenge. Outcomes in the post-abiraterone cohort are presented, as well as updated results from the post-enzalutamide cohort and an exploratory AR-V7 analysis. RESULTS AND LIMITATIONS: No statistically significant difference in PSA50 response rates to BAT was observed (30% [post-enzalutamide cohort] vs 17% [post-abiraterone cohort], p = 0.4). However, PSA50 responses to AR-targeted therapy rechallenge were higher in the post-enzalutamide cohort (68% vs 16%, p = 0.001). The median time from enrollment to progression following rechallenge with AR-targeted therapy (ie, progression-free survival 2; PFS2) was longer in the post-enzalutamide versus post-abiraterone patients (12.8 vs 8.1 mo, p = 0.04). Outcomes were worse in patients with detectable AR-V7 in circulating tumor cells (median PFS2: 10.3 vs 7.1 mo, p = 0.005). CONCLUSIONS: BAT shows clinical activity in mCRPC patients and may be more effective at resensitizing to enzalutamide versus abiraterone. PATIENT SUMMARY: BAT is well tolerated in metastatic castration-resistant prostate cancer patients. The type of prior AR-targeted therapy might affect response to BAT as well as AR-therapy rechallenge. BAT followed by AR-targeted therapy rechallenge did not improve outcomes in AR-V7-positive patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Markowski MC, Wang H, Sullivan R, et al. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol. 2020. PMID: 32624280. doi:10.1016/j.eururo.2020.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。